Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study

por Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y, Tsai J, Fitzgerald A, Takai K, Higuchi T
Publicado 2021

Natural reduced water suppressed anxiety and protected the heightened oxidative stress in rats

por Masuda K, Tanaka Y, Kanehisa M, Ninomiya T, Inoue A, Higuma H, Kawashima C, Nakanishi M, Okamoto K, Akiyoshi J
Publicado 2017

Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study

por Sogabe M, Okahisa T, Kurihara T, Kagawa M, Kagemoto K, Kida Y, Tomonari T, Taniguchi T, Okamoto K, Miyamoto H, Sato Y, Nakasono M, Takayama T
Publicado 2021

Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan

por Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Matsuda H, Suzuki Y, Ozeki Y, Okamoto K, Sagae T, Someya T
Publicado 2020

Attitudes toward metabolic adverse events among patients with schizophrenia in Japan

por Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Matsuda H, Suzuki Y, Minami Y, Ozeki Y, Okamoto K, Sagae T, Someya T
Publicado 2016